CAJ | 학술논문

目的：分析研究肝动脉栓塞联合三维放射针对治疗肝癌的治疗效果。方法选取2010年10月到2012年12月的60例确诊肝癌不能实施手术切除患者资料进行回顾性分析，为患者实施肝动脉栓塞治疗1-3次，之后实施三维放射治疗，按照肿瘤治疗效果判定标准对患者的近期治疗效果进行评价，对患者的生存率实施远期治疗效果评价，研究治疗近期以及远期的治疗效果。结果60例患者全部完成治疗，其中12例患者的病情得到完全缓解，28例患者的病情得到部分缓解，9例患者的病情稳定，5例患者病情进展，6例患者死亡。治疗之后对患者实施随访1年，患者的生存率为90.0%。结论针对不能实施手术治疗的肝癌患者进行肝动脉栓塞联合三维放射治疗，不但可以有效的控制患者的病情，对于患者的副作用相对较小，而且患者的耐受性好，值得在临床中加以推广使用。
목적：분석연구간동맥전새연합삼유방사침대치료간암적치료효과。방법선취2010년10월도2012년12월적60례학진간암불능실시수술절제환자자료진행회고성분석，위환자실시간동맥전새치료1-3차，지후실시삼유방사치료，안조종류치료효과판정표준대환자적근기치료효과진행평개，대환자적생존솔실시원기치료효과평개，연구치료근기이급원기적치료효과。결과60례환자전부완성치료，기중12례환자적병정득도완전완해，28례환자적병정득도부분완해，9례환자적병정은정，5례환자병정진전，6례환자사망。치료지후대환자실시수방1년，환자적생존솔위90.0%。결론침대불능실시수술치료적간암환자진행간동맥전새연합삼유방사치료，불단가이유효적공제환자적병정，대우환자적부작용상대교소，이차환자적내수성호，치득재림상중가이추엄사용。
Objective Analysis of transcatheter arterial chemoembolization combined with radiotherapy for the treatment of liver cancer. Methods 60 cases of hepatocellular carcinoma from 2010 October to 2012 December,not the implementation of operation resection were retrospectively analyzed,the implementation of hepatic artery embolization in the treatment of 1-3 patients,after the implementation of three-dimensional radiotherapy,according to tumor treatment effect evaluation standard to evaluate the short-term effects of treating patients,implementation of the evaluation of long-term curative effect rate of patients study on the treatment of survival,the short term and long term therapeutic effect.Results 60 patients completed the treatment,the disease in 12 patients obtained complete remission,28 cases were patients with partial remission,9 patients with stable disease, 5 patients the disease progressed, 6 patients died. After the treatment of patients with follow-up of 1 years,the survival rate of the patients was 90%.Conclusion transcatheter arterial chemoembolization combined with three-dimensional radiotherapy for treatment in patients with hepatocellular carcinoma operation can not be implemented,not only can effectively control the patients condition,side effects to the patients is relatively small,and the tolerance of patients,it is worth to be promoted in clinical use.